Chimerix (NASDAQ:CMRX - Get Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01, Zacks reports. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million.
Chimerix Price Performance
Shares of NASDAQ CMRX traded up $0.01 during mid-day trading on Tuesday, reaching $8.51. 1,234,582 shares of the company's stock were exchanged, compared to its average volume of 2,108,136. The firm has a 50-day moving average price of $5.55 and a two-hundred day moving average price of $2.96. The firm has a market capitalization of $765.36 million, a price-to-earnings ratio of -9.05 and a beta of 0.32. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.52.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on CMRX shares. StockNews.com initiated coverage on Chimerix in a research report on Sunday. They set a "hold" rating on the stock. Wedbush reaffirmed a "neutral" rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Jefferies Financial Group reiterated a "hold" rating and issued a $8.50 target price (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright restated a "neutral" rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.
View Our Latest Analysis on CMRX
Insider Activity at Chimerix
In related news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is owned by company insiders.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Stories
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
